Sustained transduction of ocular cells with a bovine immunodeficiency viral vector
- PMID: 12162813
- DOI: 10.1089/104303402760128531
Sustained transduction of ocular cells with a bovine immunodeficiency viral vector
Abstract
Human immunodeficiency viral (HIV) vectors mediate long-term transduction of many types of nondividing cells in vivo. Bovine immunodeficiency virus (BIV) is a lentivirus that shares many characteristics with HIV, but does not cause human disease. In this study, we investigated the potential of BIV vectors for ocular gene therapy. An enhanced green fluorescent protein (eGFP)-encoding reporter gene was packaged in recombinant BIV vector (BIV.eGFP). Adult C57BL/6 mice were given an intravitreous (5 x 10(4) or 5 x 10(5) transducing units [TU]) or subretinal (5 x 10(5) TU) injection of BIV.eGFP and then GFP expression was assessed at several time points. In vivo examinations of mice showed that subretinal injection of BIV.eGFP resulted in strong expression of GFP from the first examination at 1 week through the final examination at 20 weeks. Only a few mice that received intravitreous injection of BIV.eGFP showed GFP expression by ocular examinations until 11-12 weeks, when most showed small areas of expression. Postmortem examinations showed prominent GFP expression in retinal pigmented epithelial (RPE) cells throughout the region of subretinal injection of vector, although occasional negatively staining RPE cells were scattered among the much more numerous, brilliantly staining cells. Ciliary epithelial cells frequently expressed GFP, as did occasional Müller cells and rarely other retinal cells. The expression was stable from the first time point (2 weeks) to the last (20 weeks). Postmortem examination of eyes given an intravitreous injection of BIV.eGFP showed transduction of cells in the corneal endothelium and a few scattered retinal cells. There was no evidence of inflammation or toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for ocular gene therapy targeting RPE cells.
Similar articles
-
In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium.Gene Ther. 2001 Nov;8(21):1665-8. doi: 10.1038/sj.gt.3301574. Gene Ther. 2001. PMID: 11895005
-
Lentiviral transduction of green fluorescent protein in retinal epithelium: evidence of rejection.Vision Res. 2002 Feb;42(4):551-8. doi: 10.1016/s0042-6989(01)00237-1. Vision Res. 2002. PMID: 11853772
-
Efficiency of lentiviral transduction during development in normal and rd mice.Mol Vis. 2006 Jul 11;12:756-67. Mol Vis. 2006. PMID: 16862069
-
Gene therapy for retinal and choroidal diseases.Expert Opin Biol Ther. 2002 Jun;2(5):537-44. doi: 10.1517/14712598.2.5.537. Expert Opin Biol Ther. 2002. PMID: 12079489 Review.
-
Subretinal Therapy: Technological Solutions to Surgical and Immunological Challenges.Front Med (Lausanne). 2022 Mar 23;9:846782. doi: 10.3389/fmed.2022.846782. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35402424 Free PMC article. Review.
Cited by
-
Non-Primate Lentiviral Vectors and Their Applications in Gene Therapy for Ocular Disorders.Viruses. 2018 Jun 9;10(6):316. doi: 10.3390/v10060316. Viruses. 2018. PMID: 29890733 Free PMC article. Review.
-
The effect of enhancers on the lentiviral transduction efficiency in the human RPE cells: Insights for advancing retinal gene therapies.Biochem Biophys Rep. 2025 Apr 14;42:102010. doi: 10.1016/j.bbrep.2025.102010. eCollection 2025 Jun. Biochem Biophys Rep. 2025. PMID: 40275964 Free PMC article.
-
[Viral and nonviral gene therapy for treatment of retinal diseases].Ophthalmologe. 2005 Aug;102(8):764-71. doi: 10.1007/s00347-005-1245-z. Ophthalmologe. 2005. PMID: 16012813 Review. German.
-
Gene transfer for neovascular age-related macular degeneration.Hum Gene Ther. 2011 May;22(5):523-9. doi: 10.1089/hum.2011.050. Hum Gene Ther. 2011. PMID: 21443427 Free PMC article. Review.
-
Cell culture processes for the production of viral vectors for gene therapy purposes.Cytotechnology. 2006 Mar;50(1-3):141-62. doi: 10.1007/s10616-005-5507-z. Epub 2006 Jun 30. Cytotechnology. 2006. PMID: 19003076 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical